GlassScriptPhysician profile
Heather S White
NPI 1730182965
$3,011.66
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $187 · 2021: $812 · 2022: $90.38 · 2023: $408 · 2024: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $714 · Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $714.39 |
| Food and Beverage | $145.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $816.49 | 2019-2024 | |
| Roche Diagnostics International LTD | $800.00 | 2021 | |
| Pfizer INC. | $160.34 | 2019-2020 | |
| Genzyme Corporation | $145.90 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $132.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $131.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $121.92 | 2019 | |
| Janssen Biotech, INC. | $108.86 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $84.95 | 2019 | |
| Genentech USA, INC. | $74.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.62 | 2019-2020 | |
| Eisai INC. | $47.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.27 | 2019 | |
| Amgen INC. | $27.24 | 2019 | |
| Coherus Oncology, INC. | $24.46 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $24.16 | 2019 | |
| Tesaro, INC. | $22.47 | 2019 | |
| Exelixis INC. | $21.90 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.42 | 2019 | |
| Celgene Corporation | $20.20 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.19 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.58 | 2019 | |
| Puma Biotechnology, INC. | $14.24 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.21 | 2019 | |
| Kite Pharma, INC. | $14.06 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.49 | 2019 | |
| Clovis Oncology, INC. | $12.64 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.